Discover and read the best of Twitter Threads about #generalizability
Most recents (2)
1/ @STARRTAKI now published in @NEJM nejm.org/doi/full/10.10… – an updated thread follows below
#starrtaki #aki #FOAMcc @nephjc
@DrRonWald @CCCTG_ @anzicsctg @UKCCRGroup @ICCCTN @CIHR_IRSC @NIHRresearch @nhmrc @HRCNewZealand 🇨🇦🇦🇺🇦🇹🇧🇪🇧🇷🇨🇳🇩🇪🇫🇮🇫🇷🇮🇪🇮🇹🇳🇿🇨🇭🇺🇸🇬🇧
#starrtaki #aki #FOAMcc @nephjc
@DrRonWald @CCCTG_ @anzicsctg @UKCCRGroup @ICCCTN @CIHR_IRSC @NIHRresearch @nhmrc @HRCNewZealand 🇨🇦🇦🇺🇦🇹🇧🇪🇧🇷🇨🇳🇩🇪🇫🇮🇫🇷🇮🇪🇮🇹🇳🇿🇨🇭🇺🇸🇬🇧
2/ Current CPGs do not make strong recommendations (Not Graded) on when to start RRT in ICU patients with AKI, in the absence of urgent indications, due largely to discrepant findings from prior RCTs (bit.ly/3fKqEZy) (bit.ly/39etR0N) @goKDIGO @NICEComms
3/ The @STARRTAKI trial is the largest multinational trial (168 sites, 15 countries) to address whether an accelerated (early) strategy compared with standard (delayed) strategy impacts mortality and kidney recovery in ICU patients with AKI #generalizability
1/
Suppose you want to extend causal inferences from a randomized trial to a target population.
Is that #transportability or #generalizability?
Issa Dahabreh and I propose an answer in this brief commentary in the European Journal of Epidemiology:
ncbi.nlm.nih.gov/pubmed/31218483
Suppose you want to extend causal inferences from a randomized trial to a target population.
Is that #transportability or #generalizability?
Issa Dahabreh and I propose an answer in this brief commentary in the European Journal of Epidemiology:
ncbi.nlm.nih.gov/pubmed/31218483
2/
For those interested in methods for extending inferences from randomized trials to a target population:
Take a look at our tutorial
arxiv.org/pdf/1805.00550…
(soon to appear in Statistics in Medicine)
You will find identification conditions AND three estimation approaches.
For those interested in methods for extending inferences from randomized trials to a target population:
Take a look at our tutorial
arxiv.org/pdf/1805.00550…
(soon to appear in Statistics in Medicine)
You will find identification conditions AND three estimation approaches.
3/
Want more?
This article in @Biometrics_ibs considers estimators to generalize inferences from individuals in randomized trials to all trial-eligible individuals:
ncbi.nlm.nih.gov/pubmed/30488513
And this article in @EpidemiologyLWW clears some confusions:
journals.lww.com/epidem/fulltex…
Want more?
This article in @Biometrics_ibs considers estimators to generalize inferences from individuals in randomized trials to all trial-eligible individuals:
ncbi.nlm.nih.gov/pubmed/30488513
And this article in @EpidemiologyLWW clears some confusions:
journals.lww.com/epidem/fulltex…
